Quantitative assessment of colorectal cancer perfusion using MDCT: Inter- and intraobserver agreement

American Journal of Roentgenology

Volumn 185, Issue 1, 2005, Pages 225-231

  Goh, Vicky ^a,b   Halligan, Steve ^a   Hugill, Jo Ann ^a   Bassett, Paul ^a   Bartram, Clive I ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD FLOW; BLOOD VOLUME; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; IMAGE ANALYSIS; INTESTINE MUCOSA PERMEABILITY; INTESTINE TRANSIT TIME; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIODIAGNOSIS; ADENOCARCINOMA; COLORECTAL TUMOR; METHODOLOGY; OBSERVER VARIATION; PERMEABILITY; RADIOGRAPHY; VASCULARIZATION;

CONTRAST MEDIUM; DIAGNOSTIC AGENT; IOPAMIDOL;

ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; CONTRAST MEDIA; FEMALE; HUMANS; IOPAMIDOL; MALE; OBSERVER VARIATION; PERMEABILITY; REGIONAL BLOOD FLOW; TOMOGRAPHY, X-RAY COMPUTED;

EID: 24644515509     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.185.1.01850225     Document Type: Article

References (29)

1. Jemal A, Tiwari RC, Murray T, et al. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29
2. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947
3. No authors listed. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10:896-903
4. Lawrence W Jr, Terz JJ, Horsley JS 3rd, Brown PW, Romero C. Chemotherapy as an adjuvant to surgery for colorectal cancer: a follow-up report. Arch Surg 1978; 113:164-168
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186
6. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65
7. Theoni RF, Laufer I. Polyps and cancer. In: Gore RM, Levine MS, Laufer I, eds. Textbook of gastrointestinal radiology, 2nd ed. Philadelphia, PA: Saunders, 2000:1160-1199
8. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization, 1979: WHO offset publication no. 48
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid rumors. J Natl Cancer Inst 2000; 92:205-216
10. Li WW. Tumor angiogenesis: molecular pathology, therapeutic targeting and imaging. Acad Radiol 2000; 7:800-811
11. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999; 81:1318-1327
12. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19:189-195
13. Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med 2004; 10:145-147
14. Nabavi DG, Cenic A, Dool J, et al. Quantitative assessment of cerebral hemodynamics using CT: stability, accuracy, and precision studies in dogs. J Comput Assist Tomogr 1999; 23:506-515,
15. Nabavi DG, Cenic A, Craen RA, et al. CT assessment of cerebral perfusion: experimental validation and initial clinical experience. Radiology 1999; 213:141-149
16. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. AJNR 2000; 21:462-470
17. Purdie TG, Henderson E, Lee TY. Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumor. Phys Med Biol 2001; 46:3161-3175
18. Gillard JH, Antoun NM, Burnet NG, Pickard JD. Reproducibility of quantitative CT perfusion imaging. Br J Radiol 2001; 74:552-555
19. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8:135-160
20. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310
21. Blomley MJ, Coulden R, Bufkin C, Lipton MJ, Dawson P. Contrast bolus dynamic computed tomography for the measurement of solid organ perfusion. Invest Radiol 1993; 28[suppl 5]:S72-S77
22. Fiorella D, Heiserman J, Prenger E, Partovi S. Assessment of the reproducibility of postprocessing dynamic CT perfusion data. AJNR 2004; 25:97-107
23. Blomley MJ, Coulden R, Dawson P, et al. Liver perfusion studied with ultrafast CT. J Comput Assist Tomogr 1995; 19:424-433
24. Miles KA, Griffiths MR. Perfusion CT: a worthwhile enhancement? Br J Radiol 2003; 76:220-231
25. Bland JM, Altman DG. Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynaecol 2003; 22:85-93
26. Erasmus JJ, Gladish GW, Broemeling L, et al. Inter- and intra-observer variability in measurement of non-small cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003; 21:2574-2582
27. Vos MJ, Uitdehaag BM, Barkhof F, et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 2003; 60:826-830
28. Maxwell RJ, Wilson J, Prise VE, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002; 15:89-98
29. Blomley M, Dawson P. Theoretical aspects and physiological models. In: Miles KA, Dawson P, Hayball MP, eds. Functional computed tomography. Oxford, UK: Isis Medical Media, 1997